维持性透析患者对SARS-CoV-2疫苗的血清反应在6个月内的变化
这项回顾性队列研究纳入某中型全国透析机构的1870例维持性透析患者,评估完全接种SARS-CoV-2疫苗后每月抗棘突IgG抗体滴度变化。无COVID-19病史者滴度随时间下降,BNT162b2接种者中位滴度从第1个月≥20降至第6个月1.96,mRNA-1273接种者从≥20降至7.99;Ad26.COV2.S接种者滴度反应低于mRNA疫苗。完全接种后2个月内达到的最高滴度与血清反应持久性相关。
要点
- 无COVID-19病史的维持性透析患者接种疫苗后抗棘突IgG滴度随时间下降。
- BNT162b2接种者中位滴度从第1个月≥20降至第6个月1.96,mRNA-1273接种者从≥20降至7.99。
- 最大滴度1-19.99者较≥20者血清反应丧失时间更短(HR 15.5,95%CI 11.7-20.7)。
核心结论
- 维持性透析患者中,疫苗诱导的血清反应随时间减弱,且各疫苗类型均如此;完全接种后早期滴度与血清反应持久性相关。
研究设计与样本
- 回顾性队列研究,纳入某中型全国透析机构中接受完整SARS-CoV-2疫苗系列且完全接种后至少检测一次抗体滴度的维持性透析患者,共1870例。
主要发现
- 1870例中1569例无既往COVID-19;无既往COVID-19者滴度随时间下降。
- 443例BNT162b2接种者中位(四分位距)抗棘突IgG滴度从完全接种后第1个月的≥20(5.89至≥20)降至第6个月的1.96(0.60-5.88)。
- 778例mRNA-1273接种者抗棘突IgG滴度从第1个月的≥20(四分位距≥20至≥20)降至第6个月的7.99(2.61至≥20)。
- 348例Ad26.COV2.S接种者在所有时间段滴度反应均低于mRNA疫苗接种者。
- 事件时间分析中,Ad26.COV2.S接种者血清反应丧失时间最短,mRNA-1273接种者最长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Although most patients receiving maintenance dialysis exhibit initial seroresponse to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, concerns exist regarding the durability of this antibody response. This study evaluated seroresponse over time. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This retrospective cohort study included patients on maintenance dialysis, from a midsize national dialysis provider, who received a complete SARS-CoV-2 vaccine series and had at least one antibody titer checked after full vaccination. IgG spike antibodies (anti-spike IgG) titers were assessed monthly with routine laboratory tests after vaccination; the semiquantitative assay reported a range between zero and ≥20 Index. Descriptive analyses compared trends over time by history of coronavirus disease 2019 (COVID-19) and vaccine type. Time-to-event analyses examined the outcome of loss of seroresponse (anti-spike IgG <1 Index or development of COVID-19). Cox regression adjusted for additional clinical characteristics. RESULTS: Among 1870 patients receiving maintenance dialysis, 1569 had no prior COVID-19. Patients without prior COVID-19 had declining titers over time. Among 443 recipients of BNT162b2 (Pfizer), median (interquartile range) anti-spike IgG titer declined from ≥20 (5.89 to ≥20) in month 1 after full vaccination to 1.96 (0.60-5.88) by month 6. Among 778 recipients of mRNA-1273 (Moderna), anti-spike IgG titer declined from ≥20 (interquartile range, ≥20 to ≥20) in month 1 to 7.99 (2.61 to ≥20) by month 6. The 348 recipients of Ad26.COV2.S (Janssen) had a lower titer response than recipients of an mRNA vaccine over all time periods. In time-to-event analyses, recipients of Ad26.COV2.S and mRNA-1273 had the shortest and longest time to loss of seroresponse, respectively. The maximum titer reached in the first 2 months after full vaccination was associated with durability of the anti-spike IgG seroresponse; patients with anti-spike IgG titer 1-19.99 had a shorter time to loss of seroresponse compared with patients with anti-spike IgG titer ≥20 (hazard ratio, 15.5; 95% confidence interval, 11.7 to 20.7). CONCLUSIONS: Among patients receiving maintenance dialysis, vaccine-induced seroresponse wanes over time across vaccine types. Early titers after full vaccination are associated with the durability of seroresponse.
引用
- Hsu CM, Weiner DE, Manley HJ, et al. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. Clin J Am Soc Nephrol. 2022. PMID: 35144972. doi:10.2215/CJN.12250921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。